Methionine restriction-induced sulfur deficiency impairs antitumour immunity partially through gut microbiota
Ming Ji,Xiaojiang Xu,Qing Xu,Yun-Chung Hsiao,Cody Martin,Svetlana Ukraintseva,Vladimir Popov,Konstantin G. Arbeev,Tom A. Randall,Xiaoyue Wu,Liz M. Garcia-Peterson,Juan Liu,Xin Xu,M. Andrea Azcarate-Peril,Yisong Wan,Anatoliy I. Yashin,Karthik Anantharaman,Kun Lu,Jian-Liang Li,Igor Shats,Xiaoling Li
DOI: https://doi.org/10.1038/s42255-023-00854-3
IF: 19.865
2023-08-04
Nature Metabolism
Abstract:Restriction of methionine (MR), a sulfur-containing essential amino acid, has been reported to repress cancer growth and improve therapeutic responses in several preclinical settings. However, how MR impacts cancer progression in the context of the intact immune system is unknown. Here we report that while inhibiting cancer growth in immunocompromised mice, MR reduces T cell abundance, exacerbates tumour growth and impairs tumour response to immunotherapy in immunocompetent male and female mice. Mechanistically, MR reduces microbial production of hydrogen sulfide, which is critical for immune cell survival/activation. Dietary supplementation of a hydrogen sulfide donor or a precursor, or methionine, stimulates antitumour immunity and suppresses tumour progression. Our findings reveal an unexpected negative interaction between MR, sulfur deficiency and antitumour immunity and further uncover a vital role of gut microbiota in mediating this interaction. Our study suggests that any possible anticancer benefits of MR require careful consideration of both the microbiota and the immune system.
endocrinology & metabolism